Medical AI Alliance
← Company Index
Biotech & Drug DiscoveryKOSDAQ 389470Orphan Drug2 approvals

Inventage Lab Inc.

Official website

Drug delivery system company behind the long-acting injectable platform IVL-DrugFluidic and the LNP delivery platform IVL-GeneFluidic.

As of 2026-10-10, Inventage Lab Inc. has 1 Korean MFDS device approval, 15 PubMed-indexed papers on record (counted by the MAA Company Index from its own matching of public databases).

Price

Change

Market cap

Business overview

Source: DART corporate disclosure

Founded in 2015 and listed on KOSDAQ in 2022, the company is a micro/nanoparticle-based drug delivery system (DDS) platform company. Built on its long-acting injectable platform IVL-DrugFluidic, it sells the veterinary heartworm preventive 'Durahart SR-3' and holds a pipeline including the male-pattern hair loss drug IVL3001, dementia drug IVL3003, and addiction treatment IVL3004, alongside the oral peptide formulation platform IVL-PePOFluidic (applied to semaglutide). IVL3001 has completed Phase 1/2a trials in Australia and is preparing for Phase 2 in Korea, and a March 2023 license-out contract extension increased the contract value by EUR 100,000.

Products & technology

  • Durahart SR-3 injectionVeterinary heartworm preventive (moxidectin)

Regulatory approvals

data.go.kr

1 Orphan Drug designations · 2022 / 1 Korean MFDS device approvals · 2016

  • OrphanIVL40022022-11-17
    Orphan Drug designation · in development20220176171
  • MFDSGraft/prosthesisRevoked2016-03-15
    Product approval · Class 4제허 16-197 호

Global clinical trials

ClinicalTrials.gov · sponsor-matched

R&D and key agreements

Source: DART corporate disclosure

IVL3001 · 남성형 탈모 · 호주 임상1상/2a상 완료, 국내 임상2상 준비 · 1-month long-acting reformulated drug on the IVL-DrugFluidic platform; Phase 1/2a completed in Australia, Phase 2 in preparation in Korea

IVL3003 · 치매 · 호주 임상1상/2상 진행 중

IVL3004 · 마약 및 알코올 중독 · 호주 임상1상 Top line 결과 발표

IVL-PePOFluidic(세마글루타이드 경구제형) · 비만/당뇨 · 연구개발 중 · Oral peptide formulation technology based on IVL-GeneFluidic; targets higher bioavailability than Novo Nordisk's Rybelsus

Key disclosures

KRX KIND via OpenDART
Show 5 more events

Publications

PubMed · affiliation-matched
Show 5 more publications

Patents

KIPRIS · applicant-matched
Show 180 more patents

AI reads

MAA server logs · IP-verified
232
Times AI engines pulled Inventage Lab Inc.'s records

Pulled records become part of each AI's index and keep feeding its answers. When an AI cites from that index, nothing reaches our server — so actual citations are uncounted here and exceed this number.

8
Fetched fresh mid-answer

Times an AI needed something not yet in its index and fetched this page fresh while answering. Citations served from the index leave no trace here.

224
Index crawls

Collected as raw material for future answers.

0
Direct AI-tool queries (MCP)

Queries from users who connected this index to their own AI.

26
live 2
Last 7 days
208
live 5
Last 30 days
232
live 8
All time
  • OpenAIChatGPT-Userlive8
  • OpenAIOAI-SearchBot210
  • PerplexityPerplexityBot8
  • GoogleGoogleOther4
  • AnthropicClaudeBot2

Measured since Aug 25, 2026 · 4 AI engines · last read Oct 8, 2026

User-agent strings can be forged, so we do not count them at face value. We count only requests matched against vendor-published IP ranges, or confirmed by forward-verified reverse DNS. MCP queries are actual calls to this index's tool endpoint.

Connect this index to your AI tool →

Connect this company index directly to your AI

Connect it to ChatGPT or Claude, and your AI queries the full record — profiles, financials, stock data, regulatory approvals, clinical trials, publications and patents — for Inventage Lab Inc. and every listed Korean medical, bio and AI company.

How to connect (MCP)
Not yet compiled: business overview. Send us materials and we will add them

Companies approved for the same productsBiotech & Drug Discovery

Ranked by how many MFDS product categories overlap. Not a ranking — a pointer to where to look.

BioPlus Co., Ltd1 shared

Founded in 2003 and KOSDAQ-listed in 2021, BioPlus develops HA-based bio medical devices and biopharmaceuticals using its proprietary MDM Technology platform.

BNC KOREA, Inc.1 shared

Founded and listed on the KOSDAQ in 2016, BNC Korea is a biohealthcare company specializing in HA fillers, botulinum toxin, and dermo-cosmetics.

DongBang Medical Co., Ltd.1 shared

KOSDAQ-listed medical device maker producing disposable acupuncture needles, cupping cups, and hyaluronic acid dermal fillers.

JETEMA Co.,Ltd.1 shared

Founded 2009, listed on KOSDAQ in 2019, JETEMA develops hyaluronic acid fillers, botulinum toxin biopharmaceuticals, and lifting threads.

METABIOMED.CO.,LTD1 shared

KOSDAQ-listed medical device company manufacturing synthetic bioresorbable suture yarn and dental root canal filling materials.

OSTEONIC Co., Ltd.1 shared

Established in 2012 and listed on KOSDAQ in 2018, Osteonic manufactures implants for the CMF, Trauma, Sports Medicine, and Spine categories.

Samyang Biopharm Corporation1 shared

Founded and KOSPI-listed in 2025, Samyang Biopharm develops medical devices, pharmaceuticals, and new drug candidates.

AHNLAB,INC.100

KOSDAQ-listed integrated security company behind the V3 antivirus and AhnLab TrusGuard and XDR solutions.

ORGANOIDSCIENCES LTD.100

Organoid-based biotech founded 2018, KOSDAQ-listed 2025, developing the ATORM-C regenerative therapeutic and ODISEI evaluation solution.

Eone Diagnomics Genome Center Co., Ltd.85

EDGC, a Korea-US joint venture of Eone Medical Foundation and Diagnomics, offers the NIPT service NICE and liquid biopsy OncoCatch.

SK Chemicals Co., Ltd.85

A diversified SK group company operating eco-friendly chemical materials alongside pharmaceutical products like Joins and vaccines through subsidiary SK Bioscience.

CG Invites Co., Ltd.85

Genomics and drug developer behind the osteoarthritis drug Acelex and the AI-driven healthcare platform Invites Loop.

Sources and updates

Counts on this page are not company-reported figures. MAA matched records from DART, the Korean MFDS, the US FDA, ClinicalTrials.gov, PubMed and KIPRIS to this company itself, by business registration number or registered name, never by name similarity. They may differ from figures the company publishes.

Company basics
Korea Exchange · DART
Business content
Compiled from disclosure filings
Approvals & clinical trials
Korean MFDS (data.go.kr) · US FDA openFDA — updated weekly
Key disclosures
KRX KIND via OpenDART exchange filings — updated daily
Global clinical trials
ClinicalTrials.gov (US NIH) — sponsor-matched, updated weekly
Financials
DART corporate disclosure filings — annual
Publications
PubMed (US National Library of Medicine) — affiliation-matched, updated daily
Patents
KIPRIS (Korea Institute of Patent Information) — applicant-matched, updated monthly
AI reads
Our server logs, IP-verified every 6 hours
AI visibility
Measured 2026-10-01

This page is compiled from public sources without the company's involvement. If anything is inaccurate or incomplete, please let us know. Materials provided by the company are labelled as such.

Request a correction or addition